Current Alzheimer ResearchCurrent Alzheimer ResearchCurrent Alzheimer Research1567-20501875-582864377410.2174/0115672050329828240805074938MedicineResearch ArticleAdvances in Developing Small Molecule Drugs for Alzheimer's DiseaseZhangWeiinfo@benthamscience.netZhangLiujieinfo@benthamscience.netLvMingtiinfo@benthamscience.netFuYuninfo@benthamscience.netMengXiaoweninfo@benthamscience.netWangMingyonginfo@benthamscience.netWangHechenginfo@benthamscience.netSchool of Basic Medical Science, Xinxiang Medical UniversitySchool of Medical Technology, Xinxiang Medical University0104202421422123107012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1567-2050/article/view/643774

Alzheimer's disease (AD) is the most common type of dementia among middle-aged and elderly individuals. Accelerating the prevention and treatment of AD has become an urgent problem. New technology including Computer-aided drug design (CADD) can effectively reduce the medication cost for patients with AD, reduce the cost of living, and improve the quality of life of patients, providing new ideas for treating AD. This paper reviews the pathogenesis of AD, the latest developments in CADD and other small-molecule docking technologies for drug discovery and development; the current research status of small-molecule compounds for AD at home and abroad from the perspective of drug action targets; the future of AD drug development.

Alzheime's diseasecomputer-aided drug design targetsβ-amyloidforkhead box protein O1small molecule drugspathogenesis.Tatulian SA. Challenges and hopes for Alzheimer’s disease. Drug Discov Today 2022; 27(4): 1027-43. doi: 10.1016/j.drudis.2022.01.016 PMID: 35121174Adav SS, Sze SK. Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling. Mol Brain 2016; 9(1): 92. doi: 10.1186/s13041-016-0272-9 PMID: 27809929Peng C, Trojanowski JQ, Lee VMY. Protein transmission in neurodegenerative disease. Nat Rev Neurol 2020; 16(4): 199-212. doi: 10.1038/s41582-020-0333-7 PMID: 322033992023 Alzheimer’s disease facts and figures. Alzheimers Dement 2023; 19(4): 1598-695. doi: 10.1002/alz.13016 PMID: 369183892022 Alzheimer’s disease facts and figures. Alzheimers Dement 2022; 18(4): 700-89. doi: 10.1002/alz.12638 PMID: 35289055Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: An update. J Cent Nerv Syst Dis 2020; 12 doi: 10.1177/1179573520907397 PMID: 32165850Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020; 396(10248): 413-46. doi: 10.1016/S0140-6736(20)30367-6 PMID: 32738937Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019; 5(1): 272-93. doi: 10.1016/j.trci.2019.05.008 PMID: 31334330Shukla R, Singh TR. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer’s disease. J Biomol Struct Dyn 2020; 38(1): 248-62. doi: 10.1080/07391102.2019.1571947 PMID: 30688165Mouchlis VD, Melagraki G, Zacharia LC, Afantitis A. Computer-aided drug design of β-secretase, γ-secretase and anti-tau inhibitors for the discovery of novel Alzheimer’s therapeutics. Int J Mol Sci 2020; 21(3): 703. doi: 10.3390/ijms21030703 PMID: 31973122Jabir NR, Rehman MT, Alsolami K, et al. Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: In pursuit of Alzheimer’s treatment. Ann Med 2021; 53(1): 2332-44. doi: 10.1080/07853890.2021.2009124 PMID: 34889159Griffiths J, Grant SGN. Synapse pathology in Alzheimer’s disease. Semin Cell Dev Biol 2023; 139: 13-23. doi: 10.1016/j.semcdb.2022.05.028 PMID: 35690535Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol 2021; 167: 382-94. doi: 10.1016/j.ijbiomac.2020.11.192 PMID: 33278431Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer’s disease. Neurotherapeutics 2022; 19(1): 173-85. doi: 10.1007/s13311-021-01146-y PMID: 34729690Thal DR, Tomé SO. The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull 2022; 190: 204-17. doi: 10.1016/j.brainresbull.2022.10.006 PMID: 36244581Lee WJ, Brown JA, Kim HR, et al. Regional Aβ- tau interactions promote onset and acceleration of Alzheimer's disease tau spreading. Neuron 2022; 110(12): 1932-1943.e5. doi: 10.1016/j.neuron.2022.03.034Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics. Nat Rev Drug Discov 2022; 21(4): 306-18. doi: 10.1038/s41573-022-00391-w PMID: 35177833Song C, Shi J, Zhang P, et al. Immunotherapy for Alzheimer’s disease: Targeting β-amyloid and beyond. Transl Neurodegener 2022; 11(1): 18. doi: 10.1186/s40035-022-00292-3 PMID: 35300725Walker LC. Aβ plaques. Free Neuropathol 2020; 11(31): 3025. doi: 10.17879/freeneuropathology-2020-3025Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future. Signal Transduct Target Ther 2023; 8(1): 248. doi: 10.1038/s41392-023-01484-7 PMID: 37386015Bellenguez C, Grenier-Boley B, Lambert JC. Genetics of Alzheimer’s disease: Where we are, and where we are going. Curr Opin Neurobiol 2020; 61: 40-8. doi: 10.1016/j.conb.2019.11.024 PMID: 31863938Bordone MP, Salman MM, Titus HE, et al. The energetic brain – A review from students to students. J Neurochem 2019; 151(2): 139-65. doi: 10.1111/jnc.14829 PMID: 31318452Sinsky J, Pichlerova K, Hanes J. Tau protein interaction partners and their roles in Alzheimer’s disease and other tauopathies. Int J Mol Sci 2021; 22(17): 9207. doi: 10.3390/ijms22179207 PMID: 34502116Venkatramani A, Panda D. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies. Int J Biol Macromol 2019; 133: 473-83. doi: 10.1016/j.ijbiomac.2019.04.120 PMID: 31004638Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: Getting trial-ready. Nat Rev Neurol 2022; 18(7): 389-99. doi: 10.1038/s41582-022-00645-6 PMID: 35379951Ovejero-Benito MC, Ochoa D, Enrique-Benedito T, et al. Pharmacogenetics of donepezil and memantine in healthy subjects. J Pers Med 2022; 12(5): 788. doi: 10.3390/jpm12050788 PMID: 35629210Li X, Jia Y, Li J, et al. Novel and potent acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease from natural (±)-7,8-dihydroxy-3-methyl-isochroman-4-one. Molecules 2022; 27(10): 3090. doi: 10.3390/molecules27103090 PMID: 35630563Calhoun A, King C, Khoury R, Grossberg GT. An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease. Expert Opin Pharmacother 2018; 19(15): 1711-7. doi: 10.1080/14656566.2018.1519022 PMID: 30244611Shi M, Chu F, Zhu F, Zhu J. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: A focus on aducanumab and lecanemab. Front Aging Neurosci 2022; 14: 870517. doi: 10.3389/fnagi.2022.870517 PMID: 35493943Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease. JAMA 2023; 330(6): 512-27. doi: 10.1001/jama.2023.13239 PMID: 37459141Pardo-Moreno T, González-Acedo A, Rivas-Domínguez A, et al. Therapeutic approach to Alzheimer’s disease: Current treatments and new perspectives. Pharmaceutics 2022; 14(6): 1117. doi: 10.3390/pharmaceutics14061117 PMID: 35745693Bateman RJ, Cummings J, Schobel S, et al. Gantenerumab: An anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alzheimers Res Ther 2022; 14(1): 178. doi: 10.1186/s13195-022-01110-8 PMID: 36447240Vukicevic M, Fiorini E, Siegert S, et al. An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: Pyroglutamate amyloid beta. Brain Commun 2022; 4(1): fcac022. doi: 10.1093/braincomms/fcac022 PMID: 35479516Dubois B, López-Arrieta J, Lipschitz S, et al. Masitinib for mild-to-moderate Alzheimer’s disease: Results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther 2023; 15(1): 39. doi: 10.1186/s13195-023-01169-x PMID: 36849969Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: A 2020–2023 update. J Biomed Sci 2023; 30(1): 83. doi: 10.1186/s12929-023-00976-6 PMID: 37784171Vemula D, Jayasurya P, Sushmitha V, Kumar YN, Bhandari V. CADD, AI and ML in drug discovery: A comprehensive review. Eur J Pharm Sci 2023; 181: 106324. doi: 10.1016/j.ejps.2022.106324 PMID: 36347444Baig MH, Ahmad K, Rabbani G, Danishuddin M, Choi I. Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders. Curr Neuropharmacol 2018; 16(6): 740-8. doi: 10.2174/1570159X15666171016163510 PMID: 29046156Wang B, Dai P, Ding D, et al. Affinity-based capture and identification of protein effectors of the growth regulator ppGpp. Nat Chem Biol 2019; 15(2): 141-50. doi: 10.1038/s41589-018-0183-4 PMID: 30559427Chan HCS, Li Y, Dahoun T, Vogel H, Yuan S. New binding sites, new opportunities for GPCR drug discovery. Trends Biochem Sci 2019; 44(4): 312-30. doi: 10.1016/j.tibs.2018.11.011 PMID: 30612897Kim EY, Im JH, Han J, Cho WJ. Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer’s disease. Bioorg Med Chem Lett 2024; 99: 129622. doi: 10.1016/j.bmcl.2024.129622 PMID: 38244940Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021; 596(7873): 583-9. doi: 10.1038/s41586-021-03819-2 PMID: 34265844Ragonis-Bachar P, Axel G, Blau S, Ben-Tal N, Kolodny R, Landau M. What can ALPHAFOLD do for antimicrobial amyloids? Proteins 2024; 92(2): 265-81. doi: 10.1002/prot.26618 PMID: 37855235Llanes LC, Kuehlewein I, França IV, da Silva LV, da Cruz Junior JW. Anticholinesterase agents for Alzheimer’s disease treatment: An updated overview. Curr Med Chem 2023; 30(6): 701-24. doi: 10.2174/0929867329666220803113411 PMID: 35927804Lv MT, Wang HC, Meng XW, et al. In silico and in vitro analyses of a novel FOXO1 agonist reducing Aβ levels via downregulation of BACE1. CNS Neurosci Ther 2024; 30(3): e14140. doi: 10.1111/cns.14140 PMID: 36892036Makarasen A, Kuno M, Patnin S, et al. Molecular docking studies and synthesis of amino-oxy-diarylquinoline derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Drug Res (Stuttg) 2019; 69(12): 671-82. doi: 10.1055/a-0968-1150 PMID: 31698495Vilar S, Sobarzo-Sánchez E, Uriarte E. In silico prediction of P-glycoprotein binding: Insights from molecular docking studies. Curr Med Chem 2019; 26(10): 1746-60. doi: 10.2174/0929867325666171129121924 PMID: 29189117Ye W, Wang W, Jiang C, Yu Q, Chen H. Molecular dynamics simulations of amyloid fibrils: An in silico approach. Acta Biochim Biophys Sin (Shanghai) 2013; 45(6): 503-8. doi: 10.1093/abbs/gmt026 PMID: 23532062Nunes RR, Fonseca AL, Pinto ACS, et al. Brazilian malaria molecular targets (BraMMT): Selected receptors for virtual high-throughput screening experiments. Mem Inst Oswaldo Cruz 2019; 114: e180465. doi: 10.1590/0074-02760180465 PMID: 30810604Muratov EN, Bajorath J, Sheridan RP, et al. QSAR without borders. Chem Soc Rev 2020; 49(11): 3525-64. doi: 10.1039/D0CS00098A PMID: 32356548Kumar A, Nandi S, Saxena AK. Antidepressant drug design on TCAs and phenoxyphenylpropylamines utilizing QSAR and pharmacophore modeling. Comb Chem High Throughput Screen 2022; 25(3): 451-61. doi: 10.2174/1386207323666200901104222 PMID: 32875980Giordano D, Biancaniello C, Argenio MA, Facchiano A. Drug design by pharmacophore and virtual screening approach. Pharmaceuticals (Basel) 2022; 15(5): 646. doi: 10.3390/ph15050646 PMID: 35631472Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Mol Divers 2021; 25(3): 1315-60. doi: 10.1007/s11030-021-10217-3 PMID: 33844136Fang J, Zhang P, Wang Q, et al. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease. Alzheimers Res Ther 2022; 14(1): 7. doi: 10.1186/s13195-021-00951-z PMID: 35012639Winchester LM, Harshfield EL, Shi L, et al. Artificial intelligence for biomarker discovery in Alzheimer’s disease and dementia. Alzheimers Dement 2023; 19(12): 5860-71. doi: 10.1002/alz.13390 PMID: 37654029Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today 2021; 26(1): 80-93. doi: 10.1016/j.drudis.2020.10.010 PMID: 33099022Subramanian M, Wojtusciszyn A, Favre L, et al. Precision medicine in the era of artificial intelligence: Implications in chronic disease management. J Transl Med 2020; 18(1): 472. doi: 10.1186/s12967-020-02658-5 PMID: 33298113Vatansever S, Schlessinger A, Wacker D, et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Med Res Rev 2021; 41(3): 1427-73. doi: 10.1002/med.21764 PMID: 33295676Ren F, Aliper A, Chen J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol 2024; 2024: 02143-0. doi: 10.1038/s41587-024-02143-0 PMID: 38459338Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine Learning Methods in Drug Discovery. Molecules 2020; 25(22): 5277. doi: 10.3390/molecules25225277 PMID: 33198233Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol 2019; 37(9): 1038-40. doi: 10.1038/s41587-019-0224-x PMID: 31477924Amarreh I, Meyerand ME, Stafstrom C, Hermann BP, Birn RM. Individual classification of children with epilepsy using support vector machine with multiple indices of diffusion tensor imaging. Neuroimage Clin 2014; 4: 757-64. doi: 10.1016/j.nicl.2014.02.006 PMID: 24936426Shi C, Dong F, Zhao G, Zhu N, Lao X, Zheng H. Applications of machine-learning methods for the discovery of NDM-1 inhibitors. Chem Biol Drug Des 2020; 96(5): 1232-43. doi: 10.1111/cbdd.13708 PMID: 32418370Zoffmann S, Vercruysse M, Benmansour F, et al. Machine learning-powered antibiotics phenotypic drug discovery. Sci Rep 2019; 9(1): 5013. doi: 10.1038/s41598-019-39387-9 PMID: 30899034Kashyap K, Siddiqi MI. Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents. Mol Divers 2021; 25(3): 1517-39. doi: 10.1007/s11030-021-10274-8 PMID: 34282519Hu Y, Zhou G, Zhang C, et al. Identify compounds’ target against Alzheimer’s disease based on in silico approach. Curr Alzheimer Res 2019; 16(3): 193-208. doi: 10.2174/1567205016666190103154855 PMID: 30605059Jamal S, Grover A, Grover S. Machine learning from molecular dynamics trajectories to predict caspase-8 inhibitors against Alzheimer’s disease. Front Pharmacol 2019; 10: 780. doi: 10.3389/fphar.2019.00780 PMID: 31354494Xie C, Zhuang XX, Niu Z, et al. Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat Biomed Eng 2022; 6(1): 76-93. doi: 10.1038/s41551-021-00819-5 PMID: 34992270Alokam R, Singhal S, Srivathsav GS, et al. Design of dual inhibitors of ROCK-I and NOX2 as potential leads for the treatment of neuroinflammation associated with various neurological diseases including autism spectrum disorder. Mol Biosyst 2015; 11(2): 607-17. doi: 10.1039/C4MB00570H PMID: 25465055Simpson DSA, Oliver PL. ROS generation in microglia: Understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants 2020; 9(8): 743. doi: 10.3390/antiox9080743 PMID: 32823544Khezri MR, Ghasemnejad-Berenji M. The role of caspases in Alzheimer’s disease: Pathophysiology implications and pharmacologic modulation. J Alzheimers Dis 2023; 91(1): 71-90. doi: 10.3233/JAD-220873 PMID: 36442198Alkanli SS, Alkanli N, Ay A, Albeniz I. CRISPR/Cas9 mediated therapeutic approach in Huntington’s disease. Mol Neurobiol 2023; 60(3): 1486-98. doi: 10.1007/s12035-022-03150-5 PMID: 36482283Imbriani P, Tassone A, Meringolo M, et al. Loss of non-apoptotic role of caspase-3 in the PINK1 mouse model of Parkinson’s disease. Int J Mol Sci 2019; 20(14): 3407. doi: 10.3390/ijms20143407 PMID: 31336695Brahadeeswaran S, Sivagurunathan N, Calivarathan L. Inflammasome signaling in the aging brain and age-related neurodegenerative diseases. Mol Neurobiol 2022; 59(4): 2288-304. doi: 10.1007/s12035-021-02683-5 PMID: 35066762Cancela S, Canclini L, Mourglia-Ettlin G, Hernández P, Merlino A. Neuroprotective effects of novel nitrones: In vitro and in silico studies. Eur J Pharmacol 2020; 871: 172926. doi: 10.1016/j.ejphar.2020.172926 PMID: 31958456Xing Y, Li A, Yang Y, Li X, Zhang L, Guo H. The regulation of FOXO1 and its role in disease progression. Life Sci 2018; 193: 124-31. doi: 10.1016/j.lfs.2017.11.030 PMID: 29158051Zhang W, Bai S, Yang J, et al. FoxO1 overexpression reduces Aβ production and tau phosphorylation in vitro. Neurosci Lett 2020; 738: 135322. doi: 10.1016/j.neulet.2020.135322 PMID: 32860886Zhang W, Bai SS, Zhang Q, et al. Physalin B reduces Aβ secretion through down-regulation of BACE1 expression by activating FoxO1 and inhibiting STAT3 phosphorylation. Chin J Nat Med 2021; 19(10): 732-40. doi: 10.1016/S1875-5364(21)60090-0 PMID: 34688463Cooper N, Ghanima W, Hill QA, Nicolson PLR, Markovtsov V, Kessler C. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets 2023; 34(1): 2131751. doi: 10.1080/09537104.2022.2131751 PMID: 36331249Ennerfelt H, Frost EL, Shapiro DA, et al. SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Cell 2022; 185(22): 4135-4152.e22. doi: 10.1016/j.cell.2022.09.030 PMID: 36257314Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: Recent advances and future perspectives. Expert Opin Drug Discov 2021; 16(9): 949-59. doi: 10.1080/17460441.2021.1909567 PMID: 33779453Dorahy G, Chen JZ, Balle T. Computer-aided drug design towards new psychotropic and neurological drugs. Molecules 2023; 28(3): 1324. doi: 10.3390/molecules28031324 PMID: 36770990Song N, Sun S, Chen K, et al. Emerging nanotechnology for Alzheimer’s disease: From detection to treatment. J Control Release 2023; 360: 392-417. doi: 10.1016/j.jconrel.2023.07.004 PMID: 37414222